361 results on '"Dragovich, Peter S."'
Search Results
2. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
3. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
4. To Market, to Market—2020: Macromolecular Therapeutics
5. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes
6. PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
7. To Market, to Market—2019: Macromolecular Therapeutics
8. To Market, to Market—2018: Small Molecules
9. To Market, To Market--2017
10. Data from Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
11. Supplementary Data from Calicheamicin Antibody–Drug Conjugates with Improved Properties
12. Supplementary Data from An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
13. Supplementary Table 1. Supplementary Figures 1 and 2. from Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
14. Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
15. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
16. Author response: Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
17. To Market, To Market--2016
18. PROTACs Targeting BRM (SMARCA2) Afford Selective In VivoDegradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
19. CryoEM reveals unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
20. Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models
21. Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
22. Antibody–Drug Conjugates for Immunology
23. Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors.
24. Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations
25. Degrader-antibody conjugates
26. Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase
27. Efficient synthesis of (1 R,2 S) and (1 S,2 R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form
28. Measuring NAD+ levels in mouse blood and tissue samples via a surrogate matrix approach using LC–MS/MS
29. Regiospecific synthesis of 1,5-disubstituted-1 H-pyrazoles containing differentiated 3,4-dicarboxylic acid esters via Suzuki coupling of the corresponding 5-trifluoromethane sulfonates
30. Calicheamicin Antibody–Drug Conjugates with Improved Properties
31. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
32. Synthesis of an optically active, bicyclic 2-pyridone dipeptide mimetic
33. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
34. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
35. An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
36. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
37. Abstract 5687: Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models
38. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates
39. Niobium(III) and (IV) Halide Complexes
40. Formal, stereoselective synthesis of hydroxyethylene dipeptide isosteres utilizing pseudoephedrine amides
41. The Crystal Structure of the RNA-Dependent RNA Polymerase from Human Rhinovirus: A Dual Function Target for Common Cold Antiviral Therapy
42. An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents
43. Spectroscopic and crystallographic characterization of (sigma 2-terpyridyl)Re(CO)3cl. 2D-NMR evidence for a linkage isomerization reaction
44. Studies on the thermal generation and reactivity of a class of (sigma, pi)-1,4-biradicals
45. Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)
46. Improved translation of stability for conjugated antibodies using an in vitro whole blood assay
47. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
48. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
49. Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody–Drug Conjugates
50. Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.